Comparing the current results to its competitors, Ginkgo Bioworks Holdings Inc reported Revenue decrease in the 1 quarter 2026 year on year by -59.7 %, despite the revenue increase by the most of its competitors of 766.85 %, recorded in the same quarter.
Ginkgo Bioworks Holdings Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 8.28 %
Ginkgo Bioworks Holdings Inc 's Comment on Competition and Industry Peers
The company faces competition from customers' internal R&D departments and other research solution providers that perform genetic engineering manually. It also competes with companies using synthetic biology technologies to develop specific products or target particular end markets. With its expansion into tools offerings in 2024, the company will compete against life science tools companies, contract research organizations (CROs), and new AI entrants in the TechBio sector. Additional competition may arise from joint ventures and partnerships between well-capitalized technology and life sciences companies. The principal competitors fall into three categories, including the traditional 'on-premises' cell programming efforts where potential customers maintain in-house cell engineering teams and capabilities, utilizing laboratory space and highly trained scientists conducting research manually with limited scale efficiencies.
July 16, 2024
Syngenta and Ginkgo Bioworks Join Forces to Revolutionize Agricultural BiotechnologyBASEL, Switzerland and BOSTON - Syngenta Crop Protection, a global leader in agricultural innovation, has partnered with Ginkgo Bioworks, a pioneering company specializing in cell programming and biosecurity, to accelerate the launch of a groundbreaking biological solution. This collaboration marks a significant milestone in the agricultural biotechnology sector, building on the successful collaboration the two companies have previously had in developing next-generation seed technology.The partnership between Syngenta and Ginkgo Bioworks aims to harness the power of microbial strains in revolutionizing agricultural practices....
March 28, 2024
:This article examines the recent announcement by Ginkgo Bioworks, a leading company in cell programming and biosecurity, regarding its successful acquisition of a contract worth up to $6 million from the Defense Advanced Research Projects Agency (DARPA). The funding will be utilized by Ginkgo Bioworks to develop novel proteins intended to regulate ice formation in extreme cold weather conditions. This article outlines the significance of the project and provides an overview of the potential applications and implications of the research.Ginkgo Bioworks, a renowned company that specializes in cell programming and biosecurity, recently received a substantial contract from DARPA, aimed at advancing ice-control...
February 28, 2024
NEWS HEADLINE:bit.bio joins Ginkgo Bioworks Technology Network to Revolutionize Cell Therapy and Drive Innovation in Biotechnology IndustryARTICLE:CAMBRIDGE, England and BOSTON - In a major development for the biotechnology industry, bit.bio, the pioneering company specializing in coding human cells for groundbreaking therapeutics, has been announced as an inaugural partner of the Ginkgo Technology Network. The network, introduced today, aims to establish an exceptional ecosystem of cutting-edge technology partners, dedicated to collaborating with Ginkgo Bioworks - a leader in cell programming and biosecurity - to deliver integrated capabilities that will foster success for customers and push the boundaries...
Publicly Traded Peers of Ginkgo Bioworks Holdings Inc
Contextlogic Inc Share Performance
+68.12%
This Year
Contextlogic Inc
Profile
LogicBio Therapeutics Inc is a biotechnology company that focuses on developing and commercializing gene editing technology to treat rare genetic diseases.
Jasper Therapeutics Inc operates in the biotechnology industry, focusing on developing stem cell-based therapies for hematopoietic and immune system disorders. Their business model involves utilizing innovative stem cell technologies and partnerships within the medical community to advance their research and bring potential treatments to patients in need.
Genenta Science S.p.A. operates on a business model focused on the development of immuno-gene therapies for the treatment of cancer. They aim to leverage their proprietary technology to genetically modify autologous hematopoietic stem cells and engineer them to express immunomodulatory protein IL-12. These modified cells are then reinfused into patients to stimulate an immune response against tumors, potentially offering a novel and personalized approach to cancer treatment.
4D Molecular Therapeutics Inc operates with a business model focused on developing innovative gene therapy products to address serious genetic diseases. The company utilizes its proprietary technology platform to design and optimize viral vectors for targeted gene delivery. With a strong commitment to research and development, 4D Molecular Therapeutics collaborates with partners in academia, industry, and patient organizations to advance transformative treatments for patients in need.
Sources:
Ginkgo Bioworks Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Ginkgo Bioworks Holdings Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
